Chromis Therapeutics, Inc. is a San Diego-based biopharmaceutical company founded in 2015. The company is focused on the development of curative treatments for chronic HBV infection, based on its advanced proprietary drug design and discovery platform. Chromis Therapeutics is seeking investment to advance its novel cccDNA inhibitor (CHR101), viral entry, and viral capsid assembly inhibitor lead candidates for the treatment of chronic HBV. The company's lead candidate, CHR101, has the potential to eradicate HBV and efficiently cure chronically infected HBV patients, compared to drugs currently on the market. The activity of CHR101 is supported by a robust discovery preclinical data package. Chromis Therapeutics operates in the Biotechnology, Health Care, and Pharmaceutical industries and is headquartered in the United States. Chromis Therapeutics' last investment was the Seed Round investment at June 6, 2016, in which the investor was Torrey Pines Investment. With its focus on developing innovative treatments for chronic HBV infection, Chromis Therapeutics presents an opportunity for investors to support the advancement of groundbreaking solutions in the biopharmaceutical industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | Unknown | 1 |
|
06 Jun 2016 |
| Seed Round | $3.00M | 1 |
|
26 Feb 2016 |
No recent news or press coverage available for Chromis Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.